01.25.23 -- These Top 2022 Global Bioprocessing Trends Will Affect The Industry In 2023

New relationship dynamics between sponsors and CDMOs contribute to new trends appearing in the outsourced activities and services, as well as the way CDMO selection decisions are made. ISR shares how CDMO selection criteria has changed over the past five years and links the attributes to the Life Science Leader’s CMO Leadership Awards categories.

The diversity and agility of API supply chains are key to ensuring that medicines can be manufactured and delivered to patients on time, even in the face of challenges and unforeseen circumstances.

With industry-leading scientific expertise and customer support, we have pioneered solutions to some of the most pressing challenges facing customers interested in adopting MAM into their organizations.

The Cooperativity Program’s goal is to help ISG clients build and strengthen their in-house departments — medical writing or otherwise — to reach their utmost potential.

CDMOs face the challenge of integrating novel technologies to deliver cost-effective innovation to the market. How a CDMO responds to the unexpected can determine the success or failure of a project.

To truly understand the way novel therapies function in living biological systems, learn about a new dimension of study that has become indispensable: spatial bioanalysis.

Biopharmaceuticals tend to be highly unstable. A pilot formulation study at the early drug substance development stage can make things considerably easier at the manufacturing stage.

Therapies based on messenger RNA, such as mRNA vaccines, have revolutionary potential. Learn more about key objectives, considerations, and strategies in mRNA manufacturing.